New Review on PROSTVAC(TM) Published by Key Investigators From NCI
01 Julio 2009 - 9:24AM
PR Newswire (US)
KVISTGAARD, Denmark, July 1 /PRNewswire-FirstCall/ -- A just
published Review in the publication "Expert Opinion on
Investigational Drugs", Volume 18, Issue 7 2009, confirms the
previous published information on PROSTVAC(TM). This is the most
comprehensive and updated Review on PROSTVAC(TM) so far. Quote from
the article: "Preliminary clinical trials have indicated negligible
toxicity, and Phase II trials have suggested a survival benefit
after treatment with PROSTVAC(TM), especially in patients with
indolent disease characteristics." Anders Hedegaard, President
& CEO of Bavarian Nordic said: "We are very pleased that the
scientific experts once again confirm their positive view on
PROSTVAC(TM) and the potential use of the vaccine in earlier stages
of the disease. We are looking forward to publish more data at a
later stage." Background information: PROSTVAC(TM) is a therapeutic
vaccine moving into late stage clinical development that has the
potential to extend the lives of people with advanced prostate
cancer. Administered subcutaneously, it induces a specific,
targeted immune response that attacks prostate cancer cells.
Conventional chemotherapy currently used to treat prostate cancer
has limited survival rates and is often associated with numerous
side effects. In contrast, PROSTVAC(TM) has the potential to extend
survival with improved quality of life. PROSTVAC is being developed
in collaboration with the National Cancer Institute under a
Cooperative Research and Development Agreement with Bavarian
Nordic's U.S.-based subsidiary, BN ImmunoTherapeutics. In clinical
trials to date PROSTVAC(TM) and related PSA containing poxviral
vaccines have been investigated in more than 500 patients for 10
years. Forward-looking statements This announcement includes
"forward-looking statements" that involve risks, uncertainties and
other factors, many of which are outside of our control that could
cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking
statements include statements concerning our plans, objectives,
goals, future events, performance and/or other information that is
not historical information. We undertake no obligation to publicly
update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by
law. About Bavarian Nordic Bavarian Nordic A/S is a leading
industrial biotechnology company developing and producing novel
vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's business
strategy is focused in three areas: biodefence, cancer and
infectious diseases. Bavarian Nordic's proprietary and patented
technology MVA-BN(R) is one of the world's safest, multivalent
vaccine vectors. Bavarian Nordic has ongoing contracts with the US
government for the late-stage development and procurement of the
company's third-generation smallpox vaccine, IMVAMUNE(R). Bavarian
Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.
For more information please visit http://www.bavarian-nordic.com/
DATASOURCE: Bavarian Nordic A/S CONTACT: Contact (media only):
Anders Hedegaard, President & CEO, Bavarian Nordic,
+45-23-20-30-64
Copyright